# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Given continued improved performance, now believes adjusted EBITDA loss will be better than $12 million versus prior oulook of ...
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34) by 52.9...
Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Blac...
Cantor Fitzgerald analyst Ross Osborn maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $5 to...
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.36) by 47.2...
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.43) by 27.9...